YongZongHan
2021-12-16
Like
Novartis jumped over 3% in premarket trading as it launched new shares buyback of up to $15 bln
免责声明：上述内容仅代表发帖人个人观点，不构成本平台的任何投资建议。
分享至
微信
复制链接
精彩评论
我们需要你的真知灼见来填补这片空白
打开APP，发表看法
APP内打开
发表看法
1
7
{"i18n":{"language":"zh_CN"},"detailType":1,"isChannel":false,"data":{"magic":2,"id":690115838,"tweetId":"690115838","gmtCreate":1639646813238,"gmtModify":1639646813460,"author":{"id":4088307063080680,"idStr":"4088307063080680","authorId":4088307063080680,"authorIdStr":"4088307063080680","name":"YongZongHan","avatar":"https://static.tigerbbs.com/edc628ae54611a951b8ede813991e9bb","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":16,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"extraTitle":"","html":"<html><head></head><body><p>Like</p></body></html>","htmlText":"<html><head></head><body><p>Like</p></body></html>","text":"Like","highlighted":1,"essential":1,"paper":1,"likeSize":7,"commentSize":1,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/690115838","repostId":1126164577,"repostType":4,"repost":{"id":"1126164577","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1639646138,"share":"https://www.laohu8.com/m/news/1126164577?lang=&edition=full","pubTime":"2021-12-16 17:15","market":"us","language":"en","title":"Novartis jumped over 3% in premarket trading as it launched new shares buyback of up to $15 bln","url":"https://stock-news.laohu8.com/highlight/detail?id=1126164577","media":"Tiger Newspress","summary":"Novartis jumped over 3% in premarket trading as it launched new shares buyback of up to $15 bln.Nova","content":"<p>Novartis jumped over 3% in premarket trading as it launched new shares buyback of up to $15 bln.<img src=\"https://static.tigerbbs.com/7efcb788671a6965cf04c7ebd432ebe9\" tg-width=\"766\" tg-height=\"560\" width=\"100%\" height=\"auto\">Novartis AG is launching a new share buyback worth up to $15 billion to be executed by the end of 2023, it said on Thursday, adding it was confident in its top-line growth and deep pipeline.</p>\n<p>The buyback is funded through the $20.7 billion the Swiss drugmaker raised by selling its nearly one-third voting stake in Roche back to its cross-town rival last month, Novartis said, adding its capital allocation strategy aimed to combine investing in core business and returning excess capital to shareholders.</p>\n<p>Novartis said it had the flexibility to return value to shareholders \"without compromising the company's capacity for value-creating bolt-on M&A, whilst providing a strong, growing dividend and reinvesting in the business\".</p>\n<p>The Swiss company confirmed it expected sales to grow by 4% or more through 2026.</p>\n<p>The share buyback, to be executed on a second trading line, is expected to start within days.</p>\n<p>Novartis will ask shareholders to approve an additional 10 billion Swiss franc ($10.81 billion) buyback authority at the annual general meeting on March 4 to cover the amount exceeding the 8.8 billion francs still available under the existing shareholder authority granted in 2021, the company said.</p>\n<p>($1 = 0.9252 Swiss francs)</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Novartis jumped over 3% in premarket trading as it launched new shares buyback of up to $15 bln</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNovartis jumped over 3% in premarket trading as it launched new shares buyback of up to $15 bln\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-12-16 17:15</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Novartis jumped over 3% in premarket trading as it launched new shares buyback of up to $15 bln.<img src=\"https://static.tigerbbs.com/7efcb788671a6965cf04c7ebd432ebe9\" tg-width=\"766\" tg-height=\"560\" width=\"100%\" height=\"auto\">Novartis AG is launching a new share buyback worth up to $15 billion to be executed by the end of 2023, it said on Thursday, adding it was confident in its top-line growth and deep pipeline.</p>\n<p>The buyback is funded through the $20.7 billion the Swiss drugmaker raised by selling its nearly one-third voting stake in Roche back to its cross-town rival last month, Novartis said, adding its capital allocation strategy aimed to combine investing in core business and returning excess capital to shareholders.</p>\n<p>Novartis said it had the flexibility to return value to shareholders \"without compromising the company's capacity for value-creating bolt-on M&A, whilst providing a strong, growing dividend and reinvesting in the business\".</p>\n<p>The Swiss company confirmed it expected sales to grow by 4% or more through 2026.</p>\n<p>The share buyback, to be executed on a second trading line, is expected to start within days.</p>\n<p>Novartis will ask shareholders to approve an additional 10 billion Swiss franc ($10.81 billion) buyback authority at the annual general meeting on March 4 to cover the amount exceeding the 8.8 billion francs still available under the existing shareholder authority granted in 2021, the company said.</p>\n<p>($1 = 0.9252 Swiss francs)</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"NVS":"诺华"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1126164577","content_text":"Novartis jumped over 3% in premarket trading as it launched new shares buyback of up to $15 bln.Novartis AG is launching a new share buyback worth up to $15 billion to be executed by the end of 2023, it said on Thursday, adding it was confident in its top-line growth and deep pipeline.\nThe buyback is funded through the $20.7 billion the Swiss drugmaker raised by selling its nearly one-third voting stake in Roche back to its cross-town rival last month, Novartis said, adding its capital allocation strategy aimed to combine investing in core business and returning excess capital to shareholders.\nNovartis said it had the flexibility to return value to shareholders \"without compromising the company's capacity for value-creating bolt-on M&A, whilst providing a strong, growing dividend and reinvesting in the business\".\nThe Swiss company confirmed it expected sales to grow by 4% or more through 2026.\nThe share buyback, to be executed on a second trading line, is expected to start within days.\nNovartis will ask shareholders to approve an additional 10 billion Swiss franc ($10.81 billion) buyback authority at the annual general meeting on March 4 to cover the amount exceeding the 8.8 billion francs still available under the existing shareholder authority granted in 2021, the company said.\n($1 = 0.9252 Swiss francs)","news_type":1},"isVote":1,"tweetType":1,"viewCount":1238,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"CN","currentLanguage":"CN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":4,"xxTargetLangEnum":"ZH_CN"},"commentList":[],"isCommentEnd":true,"isTiger":false,"isWeiXinMini":false,"url":"/m/post/690115838"}
精彩评论